FDA Approval Activities for this Drug…

Zerit XR (stavudine) Extended-Release Capsules, 37.5 mg, 50 mg, 75 mg, and 100 mg, Bristol-Myers Squibb Company NDA 21-453 12/31/02 1/30/03 4/9/03 ZERIT (stavudine) Capsules and Pediatric Solution (POS). Bristol-Myers Squibb Company NDA 20-412/S15 10/16/01 4/22/03 ZERIT (stavudine) Capsules and Pediatric Solution (POS), Bristol-Myers Squibb Company NDA 20-412/S16 & 20-413/S7 3/29/02 4/8/02 3/29/02 ZERIT (stavudine) Capsules and Pediatric Solution (POS). Bristol-Myers Squibb Company NDA 20-412/S17, S18 & 20-413/S8, S9 2/20/02 2/21/02 ZERIT (stavudine) for Solution Bristol-Myers Squibb Company NDA 20-413/S6 Zerit (stavudine) Capsules, Bristol-Myers Squibb | Zerit (stavudine) Powder for Oral Solution, Bristol-Myers Squibb | Zerit XR Extended-Release, (stavudine) Capsules Bristol-Myers Squibb | ZERIT (stavudine) extended release capsules, Bristol-Myers Squibb, Labeling Revision

For the latest approval information, please locate this drug using this index.